Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)
-
Published:2024-06
Issue:
Volume:15
Page:100164
-
ISSN:2666-3961
-
Container-title:Endocrine and Metabolic Science
-
language:en
-
Short-container-title:Endocrine and Metabolic Science
Author:
Jammah Anwar,
Roushdy Nagwa,
Gamil Mohamed,
Diab Nidal Abu,
Abdelmonaem Naglaa,
Safarini Saher,
Gadallah Mohamed,
Zaid Nedal Abu,
Shihadeh Yahya,
Saeed Mohamed,
Sadik Jamaa,
Akil YasserORCID
Reference45 articles.
1. Standards of medical Care in Diabetes—2022;9. Pharmacologic Approaches to Glycemic Treatment;Diabetes Care,2022
2. Abdelhaleem IA, Salamah HM, Alsabbagh FA, Eid AM, Hussien HM, Mohamed NI, et al. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Diabetes & Metabolic Syndrome n.d.;15:102323. doi:https://doi.org/10.1016/j.dsx.2021.102323.
3. Diabetes mellitus in Saudi Arabia: A review of the recent literature;Abdulaziz Al Dawish;Curr. Diabetes Rev.,2016
4. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes;Ahrén;Vasc. Health Risk Manag.,2013
5. Obesity and poor glycemic control in patients with type 2 diabetes;Anari;International Journal of Research in Medical Sciences,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献